MicroRNA Changes During Breast Cancer Treatment
Author Information
Author(s): Patury Carine Bispo, Santos Brenda Luanny Maia, Matos Anna Lucia Carvalho, Slabi José, Gastalho Luciene Cristina Campos, Kaneto Carla Martins
Primary Institution: Universidade Estadual de Santa Cruz
Hypothesis
The study aims to evaluate the expression of specific microRNAs in breast cancer patients undergoing neoadjuvant treatment.
Conclusion
The study found that there is a deregulation of miR-21, miR-221, and miR-451 during neoadjuvant treatment in breast cancer patients.
Supporting Evidence
- 96% of the study group had non-special subtype breast cancer.
- 88.9% of participants had locally advanced tumors.
- 40.7% were luminal tumors, 33.3% were HER-2-positive, and 26% were triple negative.
Takeaway
This study looked at how certain tiny molecules in the blood change when women with breast cancer get treatment. It found that some of these molecules behave differently during treatment.
Methodology
The study was prospective and observational, analyzing blood samples for microRNA expression using qRT-PCR and comparing breast cancer patients with a control group.
Potential Biases
Potential bias due to the non-standardization of microRNA evaluation methods.
Limitations
The study had a small sample size and did not pair comorbidities between groups.
Participant Demographics
All participants were female, aged between 34 and 73 years, with a mean age of 50.11 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website